AARTI DRUGS
|
AARTI DRUGS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 17.96 | 22.14 | 30.09 | 60.69 | 38.06 |
| CEPS(Rs) | 23.40 | 27.54 | 35.44 | 20.40 | 14.03 |
| DPS(Rs) | 1.00 | 1.00 | 2.50 | 2.00 | 1.00 |
| Book NAV/Share(Rs) | 128.77 | 111.92 | 98.01 | 280.04 | 230.45 |
| Tax Rate(%) | 25.79 | 24.06 | 24.01 | 23.69 | 31.50 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.39 | 13.36 | 20.44 | 14.70 | 13.51 |
| EBIT Margin(%) | 9.62 | 11.81 | 18.34 | 12.33 | 11.18 |
| Pre Tax Margin(%) | 8.25 | 10.85 | 17.13 | 10.26 | 8.39 |
| PAT Margin (%) | 6.12 | 8.24 | 13.01 | 7.83 | 5.75 |
| Cash Profit Margin (%) | 7.98 | 10.25 | 15.33 | 10.53 | 8.48 |
| Performance Ratios | |||||
| ROA(%) | 7.19 | 10.32 | 16.78 | 9.33 | 6.31 |
| ROE(%) | 14.93 | 21.03 | 35.81 | 23.65 | 17.97 |
| ROCE(%) | 15.49 | 20.75 | 34.52 | 21.39 | 17.01 |
| Asset Turnover(x) | 1.17 | 1.25 | 1.29 | 1.19 | 1.10 |
| Sales/Fixed Asset(x) | 2.29 | 2.19 | 2.02 | 1.81 | 1.66 |
| Working Capital/Sales(x) | 4.86 | 5.49 | 4.67 | 6.43 | 8.07 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.44 | 0.46 | 0.49 | 0.55 | 0.60 |
| Receivable days | 108.50 | 95.71 | 88.41 | 95.71 | 97.45 |
| Inventory Days | 70.03 | 69.00 | 62.71 | 57.80 | 61.36 |
| Payable days | 95.49 | 90.28 | 95.27 | 92.63 | 90.28 |
| Valuation Parameters | |||||
| PER(x) | 18.81 | 19.37 | 23.09 | 2.08 | 4.21 |
| PCE(x) | 14.44 | 15.58 | 19.61 | 6.20 | 11.41 |
| Price/Book(x) | 2.62 | 3.83 | 7.09 | 1.81 | 2.78 |
| Yield(%) | 0.30 | 0.23 | 0.36 | 0.40 | 0.16 |
| EV/Net Sales(x) | 1.37 | 1.80 | 3.16 | 0.86 | 1.29 |
| EV/Core EBITDA(x) | 11.95 | 13.05 | 15.31 | 5.81 | 9.43 |
| EV/EBIT(x) | 14.26 | 15.27 | 17.23 | 6.96 | 11.53 |
| EV/CE(x) | 1.54 | 2.03 | 3.86 | 0.98 | 1.38 |
| M Cap / Sales | 1.15 | 1.60 | 3.01 | 0.65 | 0.97 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 9.14 | 15.49 | 19.31 | 15.71 | 25.52 |
| Core EBITDA Growth(%) | -9.38 | -22.70 | 66.63 | 25.16 | 5.13 |
| EBIT Growth(%) | -11.07 | -25.65 | 77.47 | 27.61 | 7.17 |
| PAT Growth(%) | -18.85 | -26.89 | 98.30 | 57.54 | 9.05 |
| EPS Growth(%) | -18.89 | -26.41 | -50.42 | 59.45 | 9.05 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.51 | 0.52 | 0.38 | 0.58 | 0.93 |
| Current Ratio(x) | 1.60 | 1.48 | 1.78 | 1.45 | 1.33 |
| Quick Ratio(x) | 1.05 | 0.92 | 1.08 | 0.93 | 0.91 |
| Interest Cover(x) | 7.04 | 12.29 | 15.07 | 5.95 | 4.01 |
| Total Debt/Mcap(x) | 0.19 | 0.14 | 0.05 | 0.32 | 0.34 |
Compare Financial Ratios of peers of AARTI DRUGS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AARTI DRUGS | ₹4,598.7 Cr | 0.8% | 11.9% | 18.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,831.0 Cr | -0.1% | -2.8% | 50.3% | Stock Analytics | |
| CIPLA | ₹113,471.0 Cr | 4.5% | -3.1% | 52.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,713.0 Cr | 4.6% | 1.4% | 22.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,960.0 Cr | 4.7% | 10.8% | 18.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,687.8 Cr | 3.1% | -4.1% | 80.4% | Stock Analytics | |
AARTI DRUGS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AARTI DRUGS | 0.8% |
11.9% |
18.5% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
